Sorrento Therapeutics (SRNE) News Today $0.0037 +0.00 (+2.78%) As of 09/5/2025 03:53 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Sorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento Therapeutics (NASDAQ:SRNE) Stock Price Passes Below 200 Day Moving Average of $0.11February 9, 2024 | marketbeat.comSorrento Therapeutics, Inc. (0L85.L)January 9, 2024 | finance.yahoo.comSorrento Therapeutics Inc SRNEQNovember 5, 2023 | morningstar.comMSorrento, Italy - Weather Forecasts | Maps | News - Yahoo WeatherOctober 14, 2023 | yahoo.comCourt rules Virpax CEO Anthony Mack breached his agreement with Sorrento TherapeuticsSeptember 7, 2023 | bizjournals.comSorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse BidAugust 8, 2023 | finance.yahoo.comWildcat Claims CNSL Shareholders Are Being Ripped Off in Weak Deal, Claiming $14 Price is RequiredJuly 13, 2023 | msn.comSorrento sees promising phase 2 results for abivertinib for lymphomaJuly 5, 2023 | seekingalpha.comSRNEQ Sorrento Therapeutics, Inc.June 22, 2023 | seekingalpha.comSorrento Therapeutics (OTC: SRNE.Q)June 14, 2023 | fool.comUBS Group AG Has $2.12 Million Stock Position in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)June 6, 2023 | marketbeat.comSorrento Therapeutics, Inc. (SRNEQ)April 24, 2023 | finance.yahoo.comSorrento Therapeutics Opponent Loses Chapter 11 Committee SeatMarch 21, 2023 | wsj.comFirm Retention Summary: Sorrento Therapeutics Inc.March 18, 2023 | wsj.comWhy Sorrento Therapeutics (SRNE) Stock Plummeted TodayMarch 15, 2023 | thestreet.comSorrento Therapeutics, Inc. (NASDAQ:SRNE) Shares Bought by Credit Suisse AGMarch 8, 2023 | marketbeat.comIs a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?March 2, 2023 | finance.yahoo.comScilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain managementFebruary 27, 2023 | finance.yahoo.comWhy Sorrento Therapeutics Stock Is Soaring TodayFebruary 22, 2023 | benzinga.comBankrupt Sorrento Therapeutics Secures Court Approval for $75M FinancingFebruary 22, 2023 | yahoo.comSorrento Therapeutics surges 28% as court nods for a $75M loanFebruary 22, 2023 | seekingalpha.comSorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CaseFebruary 21, 2023 | finance.yahoo.comSorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)February 18, 2023 | finance.yahoo.comThinking about buying stock in Esports Entertainment, Marathon Digital, Sorrento Therapeutics, Nu Holdings, or ContextLogic?February 17, 2023 | benzinga.comWhy Kim Jong Un’s Daughter Is All Over North Korean MediaFebruary 15, 2023 | finance.yahoo.comSorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerFebruary 14, 2023 | finance.yahoo.comSorrento Therapeutics Files For BankruptcyFebruary 14, 2023 | uk.finance.yahoo.comHot Stocks: TDC climbs on earnings; FSLY upgrade; TWLO restructuring; SRNE bankruptcyFebruary 13, 2023 | seekingalpha.comSorrento Therapeutics Files for Bankruptcy to Halt $173 Million Licensing JudgmentsFebruary 13, 2023 | wsj.comSorrento Therapeutics stock plummets more than 60% on news of bankruptcy filingFebruary 13, 2023 | proactiveinvestors.comSorrento Therapeutics Stock Is Sinking: What's Going On?February 13, 2023 | markets.businessinsider.comSorrento Therapeutics Stock Nosedives After Filing Bankruptcy PaperworkFebruary 13, 2023 | finance.yahoo.comJoint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.February 13, 2023 | finance.yahoo.comThinking about buying stock in Sorrento Therapeutics, Bed Bath & Beyond, C3.ai, Expion360, or SoundHound AI?February 13, 2023 | benzinga.comSorrento sheds 60% after bankruptcy filing (update)February 13, 2023 | msn.comA Sorrento Therapeutics, Inc. (NASDAQ:SRNE) insider increased their holdings by 2.0% last yearFebruary 13, 2023 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineFebruary 12, 2023 | finance.yahoo.comSorrento Therapeutics, Inc. (NASDAQ:SRNE) Shares Bought by Victory Capital Management Inc.February 10, 2023 | marketbeat.comSG Americas Securities LLC Has $84,000 Holdings in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)February 9, 2023 | marketbeat.com5 Hot Healthcare Stocks to Buy NowFebruary 3, 2023 | insidermonkey.com Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRNE Media Mentions By Week SRNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRNE News Sentiment▼0.000.72▲Average Medical News Sentiment SRNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRNE Articles This Week▼00▲SRNE Articles Average Week Get the Latest News and Ratings for SRNE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sorrento Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TherapeuticsMD News Today Longeveron News Today HCW Biologics News Today Bullfrog AI News Today IM Cannabis News Today Marker Therapeutics News Today Leap Therapeutics News Today Moleculin Biotech News Today GeoVax Labs News Today Flora Growth News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRNE) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRNE Stock Alerts